Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:28:50.197Z.
Calculation as of: 2026-10-06T22:28:50.197Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8bdc5b92b4d262cc13a98cf6604682d0e20af2b1e6f35657b788ee16300fad7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Talphera, Inc.
Market Cap
$57.61M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Talphera, Inc. (TLPH) | $57.61M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A |
| Aldeyra The (ALDX)vs › | $55.25M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
